A
Ancora Heart
Ancora Heart is dedicated to helping people with heart failure feel better and live longer
About Ancora Heart
Ancora Heart is a healthcare startup that operates in the medical technology sector, specifically focusing on innovative therapies for heart failure patients. Their primary product is the AccuCinch Ventricular Restoration System, a breakthrough medical device that has received designation from the FDA. This system is designed to improve the quality of life for patients suffering from heart failure, particularly those who have not found relief from other treatments.
The company's target market is patients with congestive heart failure (CHF), a condition characterized by symptoms such as extreme fatigue, difficulty breathing, and memory loss. Ancora Heart's business model revolves around the development, clinical testing, and eventual commercialization of the AccuCinch system.
The AccuCinch system works by initiating a process of reverse remodeling in patients who have heart failure with reduced ejection fraction (HFrEF), a condition where the heart muscle doesn't contract effectively and less oxygen-rich blood is pumped out to the body. Early clinical data has shown the potential of the system to improve patients' functional capacity and overall quality of life.
Currently, Ancora Heart is conducting a randomized, controlled clinical trial, The CORCINCH-HF Study, to further evaluate the benefits of the AccuCinch system. The company generates revenue through the sale of the AccuCinch system to healthcare providers once it has received full regulatory approval and commercialization.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2001
- Headquarters
- Santa Clara, United States
- Employees
- 74
- Open positions
- None listed
- Dealroom signal
- 39.2/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Cardiology and cardiovascular, Tech for Hospitals and Clinics, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jul 2021 | $80M | $320M | Savitr Capital · sio capital management | — |
| LATE VCOther financing | Dec 2018 | $24M | $94M | Undisclosed | — |
Growth signals
Latest recorded traffic for Ancora Heart is 520 monthly website visits, down 71.1% over the last three months. Ancora Heart's team declined 5.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
Savitr Capital
sio capital management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ancora Heart on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ancora Heart’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.